Suppr超能文献

[α-肾上腺素能阻滞剂在急性尿潴留治疗中的辅助作用]

[Alpha-adrenergic blockers as a support in the treatment of acute urinary retention].

作者信息

Altarac Silvio

机构信息

Uroloski odjel Opće bolnice Zabok, Trg Dragutina Domjanića 6, 49 210 Zabok.

出版信息

Lijec Vjesn. 2006 Jul-Aug;128(7-8):233-7.

Abstract

Catheterization remains the standard management of acute urinary retention (AUR), followed by a trial without catheter (TWOC) or prostatectomy in men who do not void spontaneously. If AUR is caused by increased sympathetic activity at the level of the prostatic smooth muscles, alpha-blockers (alpha-1 adrenoreceptor antagonists) should increase the likelihood of a successful trial without catheter (TWOC) following AUR. Alpha-blockers effectively reduce the symptoms associated with benign prostatic hyperplasia (BPH) and improve the urodynamic parameters of obstruction. They may diminish the incidence of AUR and the need for prostatectomy in symptomatic men. The adventage of tamsulosin and slow-release alfuzosin over doxazosin and terazosin in the management of AUR is that a therapeutic dose can be administered at the onset of AUR, thereby reducing the time for attempting catheter removal.

摘要

导尿术仍然是急性尿潴留(AUR)的标准治疗方法,对于不能自主排尿的男性,随后进行无导尿管试验(TWOC)或前列腺切除术。如果AUR是由前列腺平滑肌水平的交感神经活动增加引起的,α受体阻滞剂(α-1肾上腺素能受体拮抗剂)应该会增加AUR后无导尿管试验(TWOC)成功的可能性。α受体阻滞剂可有效减轻与良性前列腺增生(BPH)相关的症状,并改善梗阻的尿动力学参数。它们可能会降低有症状男性AUR的发生率以及前列腺切除术的必要性。在AUR的治疗中,坦索罗辛和缓释阿夫唑嗪相对于多沙唑嗪和特拉唑嗪的优势在于,在AUR发作时即可给予治疗剂量,从而减少尝试拔除导尿管所需的时间。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验